Eikon Therapeutics' IPO

Q: When does the lock-up end?

Eikon Therapeutics' IPO lock-up ends Aug 3, 2026. Its final prospectus says: “.”

Listed Feb 5, 2026 at $18 on Nasdaq as EIKN.

Offer price

$18

Market cap

$972M

21,177,600

Today 69% below its $18 offer price; its first day closed -16.7%.

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See EIKN ranked, live

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Feb 5, 2026.

What does Eikon Therapeutics do?

“We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs.”

From its final prospectus (424B4), filed Feb 5, 2026

Eikon Therapeutics' facts, each with its source
Fact	Eikon Therapeutics
Incorporated	Delaware, 2019From its final prospectus (424B4) of Feb 5, 2026
Headquarters	Millbrae, CaliforniaFrom its final prospectus (424B4) of Feb 5, 2026
Employees	384 full-time, as of December 31, 2025From its final prospectus (424B4) of Feb 5, 2026
Website	eikontx.comFrom its final prospectus (424B4) of Feb 5, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Eikon Therapeutics' facts, each with its source
Fact	Eikon Therapeutics
Shares offered	21,177,600From the final prospectus (424B4) filed Feb 5, 2026
Offer price	$18 a shareFrom the final prospectus (424B4) filed Feb 5, 2026
Raised at that price	$381 millionFrom the final prospectus (424B4) filed Feb 5, 2026
Underwriters' discount	$26.7 millionFrom the final prospectus (424B4) filed Feb 5, 2026
Underwriters' option	3,176,640 more sharesFrom the final prospectus (424B4) filed Feb 5, 2026
Underwriters	J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and MizuhoFrom the final prospectus (424B4) filed Feb 5, 2026, as its cover names them
Exchange	Nasdaq Global Select Market, as EIKNFrom the final prospectus (424B4) filed Feb 5, 2026
Shares outstanding after	53,984,337From the final prospectus (424B4) filed Feb 5, 2026
Market cap at the offer price	$972 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Eikon Therapeutics' facts, each with its source
Fact	Eikon Therapeutics
Revenue	None from product sales yetFrom its final prospectus (424B4) of Feb 5, 2026: it has not generated any revenue from product sales
Last preferred stock	Series D preferredFrom its final prospectus (424B4) of Feb 5, 2026

What risks does Eikon Therapeutics name first?

“We are a late clinical-stage biotechnology company with a limited operating history and a history of incurring substantial net losses, have no products approved for commercial sale, have never generated revenue from product sales, and may never achieve or maintain profitability.”
“Our recurring losses from operations and financial condition raise substantial doubt about our ability to continue as a going concern.”
“Even if this offering is successful, we will require substantial additional capital to finance our operations and achieve our business objectives.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Eikon Therapeutics' IPO

Eikon Therapeutics' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Jan 9, 2026	Form S-1, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Jan 28, 2026	exchange registration (Form 8-A), SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Jan 30, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), filed Feb 5, SEC EDGAR	Feb 4, 2026	final prospectus (424B4), filed Feb 5, SEC EDGAR
First tradeMassive's IPO calendar	Feb 5, 2026	Massive's IPO calendar
Lock-up endsfinal prospectus, SEC EDGAR: “”	Aug 3, 2026	final prospectus, SEC EDGAR: “”

How did its first days trade?

From its daily bars, each close against its $18 offer price.

Eikon Therapeutics' first sessions
Day	Open	Close	From the offer
Feb 5	$17.05	$15	-16.7%
Feb 6	$15.22	$14.50	-19.4%
Feb 9	$15.87	$14.55	-19.2%
Feb 10	$14.56	$13.59	-24.5%
Feb 11	$13.60	$14.49	-19.5%

What is Eikon Therapeutics' Quality Score?

Below Average

182 trading days so far; 1 of the 14 checks wait for more history.

EIKN's page, with every reason behind its score

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
Bambusa TherapeuticsNasdaq: BBTX · No day yet	$15 to $17About $796M	$796Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

Eikon Therapeutics IPO questions

When is Eikon Therapeutics' IPO?

Listed Feb 5, 2026 at $18 on Nasdaq as EIKN.

What is Eikon Therapeutics' IPO price?

Eikon Therapeutics' IPO priced at $18 a share, per its final prospectus of Feb 5, 2026.

How many shares is Eikon Therapeutics selling?

21,177,600 shares, and the underwriters may buy 3,176,640 more, per its final prospectus (424B4).

Who are the underwriters?

J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho, as the prospectus's cover names them.

When does the lock-up end?

Eikon Therapeutics' IPO lock-⁠up ends Aug 3, 2026. Its final prospectus says: “.”

Does Breakaway rate Eikon Therapeutics?

Eikon Therapeutics has a Quality Score of 0 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Eikon Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and February 2026's listings.